Table 3.
Multivariate analysis of PFS on pretreatment quality of life of QLQ-C30 among 501 patients with nasopharyngeal carcinoma
| HR | 95%CI | P | |
|---|---|---|---|
| Age | 1.200 | 0.692–2.079 | 0.516 |
| Gender | 0.772 | 0.395–1.510 | 0.450 |
| Marriage | 1.470 | 0.458–4.719 | 0.517 |
| Education | 1.197 | 0.940–1.525 | 0.145 |
| Smoking history | 0.951 | 0.518–1.747 | 0.872 |
| Alcohol history | 0.787 | 0.324–1.910 | 0.596 |
| T stage | 1.383 | 0.684–2.794 | 0.367 |
| N stage | 1.979 | 1.156–3.388 | 0.013 |
| Pre-treatment EBV DNA | 1.451 | 0.866–2.431 | 0.157 |
| Post-treatment EBV DNA | 3.130 | 1.563–6.267 | 0.001 |
| Pain | 1.015 | 0.995–1.035 | 0.146 |
| Teeth | 0.984 | 0.971–0.998 | 0.026 |
| Felt ill | 1.004 | 1.001–1.007 | 0.012 |
Abbreviations: PFS Progression free survival, HR Harsard ratio